

Grids for life sciences: status and perspectives

V. Breton

CNRS-IN2P3

Teratec 2009

Credit: A. Da Costa, P. De Vlieger, J. Salzemann

<http://clrpcsv.in2p3.fr>



Introduction

Plateforme de Calcul pour les Sciences du Vivant



- **Grid technology provides services to do science differently, opens new avenues for**
 - Large scale on demand computing
 - Secure data sharing
 - dynamic data analysis
- **Goals of my talk**
 - Share some of our ideas for using grid services in life sciences and healthcare
 - Share my enthusiasm for what is ahead of us

All grid applications described in this talk use gLite as grid middleware

Table of content

Plateforme de Calcul pour les Sciences du Vivant



- **Introduction**
- **Grid added value for**
 - Large scale computing
 - Distributed data management
 - Dynamic data analysis
- **WISDOM, grid-enabled *in silico* drug discovery**
- **Cancer surveillance network**
- **Emerging disease surveillance network**
- **Conclusion**

Grid services have made huge progresses

Plateforme de Caen pour les Sciences du Vivant



- **Distributed computing has been available for 5 years for scientific production**
 - ☺ : access to very large number of CPUs (>20.000 for biomed Virtual Organization)
 - ☺ : web service APIs lead to improved interoperability (EGEE, OSG, Digital Ribbon, ...)
 - ☹: job efficiency and resource stability are still a problem
 - ☹: MPI is still available on a limited number of clusters (<10% of CPUs on EGEE biomed VO)
- **Distributed data management has recently become available (AMGA)**
 - ☺: secured access
 - ☺: easy installation
 - ☺: good performances
 - ☹: critical mass of developers for software maintenance and evolution

What can I do with these services I could not do before ?

- **Possibility to scale up by one or two orders of magnitude the volume of computations**
 - On demand access to > 20.000 CPU cores instead of cluster
 - Freedom to think big
- **Use cases**
 - Protein structure computations (e-NMR)
 - From docking 1000 drug-like molecules to testing all the compounds currently available on market
 - From updating monthly to updating daily a molecular biology database
 - From studying the impact of single DNA mutations (SNPs) to multiple correlated mutations (Haplotypes) on diseases

Genome Wide Haplotype analyses of human complex diseases with the EGEE grid

Plateforme de Calcul pour les Sciences du Vivant





- Goal: study the impact of DNA mutations on human coronary diseases
- Very CPU demanding analysis to study the impact of correlated (double, triple) DNA mutations
- Deployment on EGEE Grid
 - 1926 CAD (Coronary Artery Diseases) patients & 2938 healthy controls
 - 378,000 SNPs (Single Nucleon Polymorphisms = local DNA mutations)
 - 8.1 millions of combinations tested in less than 45 days (instead of more than 10 years on a single Pentium 4)
- Results published in ***Nature Genetics March 2009*** (D. Tregouet et al)
 - Major role of mutations on chromosome 6 was confirmed

Application: recalculating protein 3D structures in PDB

Plateforme de Calcul pour les Sciences du



- The PDB data base gathers publicly available 3D protein structures
 - Full of bugs
- Goal: redo the structures by recalculating the diffraction patterns



PDB-files	42.752
X-ray structures	36.124
Successfully recalculated	~36.000
Improved R-free	12.500/17000
CPU time estimate	21.7 CPU years
Real time estimate	1 month on Embrace VO on EGEE

Share my data while keeping them !

Plateforme de Calcul pour les Sciences du Vivant



- **Share securely data without having to put them in a central repository**
 - Data are left where they are produced
 - Authorized users have a customized view of a subset of the data
 - Data owners keep a full control of their data
- **Use cases**
 - Federation of mammography databases (MammoGrid) to improve cancer detection
 - Federation of brain medical image databases (BIRN, NeuroLog, NeuGrid) for neurosciences

Monitoring and alert

Plateforme de Calcul pour les Sciences du Vivant



- **Coupling of grid data management and computing services allows continuous**
 - Data collection
 - Data analysis
 - Updated modeling
 - Towards decision making
- **Use cases**
 - Tsunami alert system
 - Flood alert system
 - Epidemiology

Table of content

Plateforme de Calcul pour les Sciences du Vivant



- **Introduction**
- **Grid added value for**
 - Large scale computing
 - Distributed data management
 - Dynamic data analysis
- **WISDOM, grid-enabled *in silico* drug discovery**
- **Cancer surveillance network**
- **Emerging disease surveillance network**
- **Conclusion**

WISDOM (World-wide In Silico Docking On Malaria) is an initiative aiming to demonstrate the relevance and the impact of the grid approach to address drug discovery for neglected and emerging diseases.



Wisdom-I

Malaria
Plasmeprin

2006

DataChallenge
Avian Flu
Neuraminidase

2007

Wisdom-II
Malaria
4 targets

2008

DataChallenge
Diabetes
Alpha-amylase

GRIDS



EGEE, Auvergrid,
TwGrid, EELA,
EuChina,
EuMedGrid

EUROPEAN PROJECTS



Embrace
EGEE
BioInfoGrid


INSTITUTES



SCAI, CNU
Academia Sinica of Taiwan
ITB, Unimo Univ., LPC, CMBA
CERN-Arda, Healthgrid, KISTI

WISDOM partners

Plateforme de Calcul pour les Sciences du Vivant




Virtual screening pipeline


Plateforme de Calcul pour les Sciences du Vivant




FLEXX/
AUTODOCK



AMBER



CHIMERA



WET LABORATORY



Molecular docking

Molecular dynamics

Complex
visualization

in vitro

in vivo



Modern Medicine

healthy patients. healthy practice.

Home Resource Centers CME/CE Medical Economics Careers Community

Oseltamivir-Resistant Flu Viruses Increasing

Resistant viruses pose lethal threat to high-risk patients

Publish date: Mar 3, 2009

 E-MAIL  PRINT  SHARE ▾

SOURCE:




TUESDAY, Mar. 3 (HealthDay News) -- The 2008 to 2009 influenza season will see a higher prevalence of oseltamivir-resistant viruses, and certain strains of the virus are highly pathogenic to high-risk patients, according to two studies published online Mar. 2 in the *Journal of the American Medical Association*. Another study reports that intranasal live attenuated influenza vaccine is associated with more medical encounters than trivalent inactivated vaccine.

Zhong Wang, Ph.D., and colleagues at the Armed Forces Health Surveillance Center in Silver Spring, Md., conducted influenza surveillance among more than one million American military personnel during the three flu seasons from 2004 to 2007, and found that subjects in all three seasons that were vaccinated using trivalent inactivated vaccine had lower incidence of pneumonia and influenza compared to live attenuated influenza vaccination or no vaccination.

Nila J. Dharan, M.D., of the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues tested the 2007-2008 season influenza A(H1N1) viruses, and found that of 1,155 viruses tested, 142 (12.3 percent) of them were resistant to oseltamivir. Preliminary data shows that 264 of 268 samples tested from the 2008-2009 season are also resistant. In another report, Jairo Gooskens, M.D., of Leiden University Medical Center in the Netherlands, and colleagues describe the transmission of oseltamivir-resistant influenza A(H1N1) viruses with the H274Y mutation in stem cell transplant and elderly patients.




Oseltamivir is an antiviral drug used in the treatment and prophylaxis of Influenzavirus A



8 variants NA predicted
by homology modelling



Autodock Docking Tool



Chemical compound
database


Deployment on EGEE grid...

Number of dockings	CPU years	Real Time	CPUs used	Produced Data size	Crunching Factor	Distribution efficiency
4 millions	100	1,5 months	1700	800 GB	900	50 % WISDOM >80% DIANE


WISDOM production environment



Plateforme de Calcul pour les Sciences du Vivant



Results obtained



(GNA) (G39)
zanamivir oseltamivir

5 known inhibitors

	T06	T01	T02	T03	T05	T07	T13
DAN	-	-	-	-	-	-	-
4AM	-	-	+	+	-	-	-
49A	+	-	+	+	+	-	-
GNA	+	-	+	-	+	-	+
G39	+	-	-	-	+	-	+

Mutation effect on the known inhibitors docking scores.

"+" sign: compound is
within top 5%

"-" sign: compound is not within the top 5%.

- ## Quick evaluation of mutation effect on inhibitor binding


Table of content

Plateforme de Calcul pour les Sciences du Vivant



- **Introduction**
- **Grid added value for**
 - Large scale computing
 - Distributed data management
 - Dynamic data analysis
- **WISDOM, grid-enabled *in silico* drug discovery**
- **Cancer surveillance network**
- **Emerging disease surveillance network**
- **Conclusion**


Breast cancer screening



Sentinel network




Plateforme de Calcul pour les Sciences du Vivant



Architecture




Plateforme de Calcul pour les Sciences du Vivant



Technical architecture



Plateforme de Calcul pour les Sciences du Vivant



Grid-enabled sentinel network for cancer surveillance,
Proceedings of Healthgrid conference 2009
Studies in Health Technology and Informatics

Collaboration: CNRS – MAAT - RSCA

Table of content


Plateforme de Calcul pour les Sciences du Vivant



- **Introduction**
- **Grid added value for**
 - Large scale computing
 - Distributed data management
 - Dynamic data analysis
- **WISDOM, grid-enabled *in silico* drug discovery**
- **Cancer surveillance network**
- **Emerging disease surveillance network**
- **Conclusion**




New human or bird case



New virus strain


« The only way to track down a virus history
Is through its imprint on the viral genome »



Genome sequencing

Molecular
Epidemiology

Virtual
Screening




Homology modelling

Molecular Epidemiology



Plateforme de Calcul pour les Sciences du Vivant

- Classification of virus strains
- Tracing of transmission of a strain (phylogeography)
- Analyses of outbreaks
 - Gene rearrangement
 - MRCA
 - dN/dS
- Analyses of pathogenesis of virus infection in humans







New virus



New genome

Virtual Screening




New sequence + informations
added to databases

Influenza grid pilot architecture




Plateforme de Calcul pour les Sciences du Vivant



WISDOM production environment



Plateforme de Calcul pour les Sciences du Vivant



Grid added value for emerging diseases

Plateforme de Calcul pour les Sciences du Vivant



- **Dynamic monitoring of the outbreak**
 - Virus evolution
 - Primer design for micro array test
 - Epidemic simulation
- ***In silico* drug discovery**
 - Grid-enabled virtual screening
 - Impact of mutations on existing drugs
 - Homology modeling
- **Epidemiology**
 - Epidemic modeling

Show case: Influenza A epidemic

Table of content

Plateforme de Calcul pour les Sciences du Vivant




- **Introduction**
- **Grid added value for**
 - Large scale computing
 - Distributed data management
 - Dynamic data analysis
- **WISDOM, grid-enabled *in silico* drug discovery**
- **Cancer surveillance network**
- **Emerging disease surveillance network**
- **Conclusion and perspectives**

- **Grid services are better than they have ever been**
 - Opportunities to do science differently or at a larger scale
- **Need for more improvements**
 - Improved grid services
 - Installation, operation and maintenance of grid services is still costly
 - *Need for expertise and time*
 - Development of scientific gateways
 - *To allow easy access to grid resources*
 - Interoperability of grid infrastructures
 - *User should be middleware agnostic*
 - Stability is still an issue
 - Towards data integration and knowledge management
 - Data integration is the real challenge for life sciences

Large resources in related disciplines

Specialist biomolecular data resource examples

plateforme de calcul pour les Sciences du vivant



Credit: G. Cameron

Model organism resource examples

